Head and Neck Cancer
PV QA 2 - Poster Viewing Q&A 2
MO_36_2489 - Persistently Elevated Soluble MHC Class I Polypeptide-Related Sequence a and Transforming Growth Factor-1 Levels Are Poor Prognostic Factors in Head and Neck Squamous Cell Carcinoma after Definitive Chemoradiotherapy
Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3
Persistently Elevated Soluble MHC Class I Polypeptide-Related Sequence a and Transforming Growth Factor-β1 Levels Are Poor Prognostic Factors in Head and Neck Squamous Cell Carcinoma after Definitive Chemoradiotherapy
J. L. Y. Chen1, Y. S. Huang1, C. W. Wang1, S. H. Kuo2, and Y. L. Lin3; 1National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, 2Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan, 3National Taiwan University Hospital, Taipei, Taiwan
Purpose/Objective(s): Impaired immune response in head and neck squamous cell carcinoma (HNSCC) allows cancer cells to successfully escape immune surveillance, resulting in tumor recurrence after definitive treatment. Hence, we evaluated the prognostic significance of immunologic inhibitory biomarkers in patients undergoing definitive chemoradiotherapy (CRT) for HNSCC.
Materials/Methods: Thirty patients were prospectively enrolled in this study. Plasma levels of soluble MHC class I polypeptide-related sequence A (sMICA) and transforming growth factor-β1 (TGF-β1) were measured before and 2 weeks after completing CRT. Plasma percent change (%) = (post-CRT plasma level – pre-CRT plasma level) / (pre-CRT plasma level). Tumor recurrence analysis considered locoregional recurrence (LRR) and distant metastasis (DM), determined by physicians and radiologists via a panel discussion. The levels of these makers were correlated with clinical outcomes via Kaplan–Meier log-rank tests and Cox proportional hazards regression model.
Results: During a median follow-up of 30.9 months, 10 patients died and LRR occurred in 4 and DM in 9 patients. Compared to patients without recurrence, patients with DM had a significantly higher increase in plasma sMICA percent change (116.8% vs 4.1%, p = 0.033) and less marked decrease in plasma TGF-β1 percent change (-6.1% vs. -35.5%, p = 0.037). Patients with LRR had a trend toward greater increase in plasma sMICA percent change compared to patients without recurrence (71.2% vs 4.1%, p = 0.092), while there was no significant difference in plasma TGF-β1 analysis. In multivariate analysis, patients with persistently elevated sMICA and TGF-β1 after CRT were more prone to distant metastases (hazard ratio: 5.1, 95% conﬁdence interval: 1.1-23.5, p = 0.039), and tended to have a poor overall survival (hazard ratio: 4.7, 95% conﬁdence interval: 0.8-26.4, p = 0.083), irrespective of tumor stage or histology grade.
Conclusion: Our results suggest that persistently elevated sMICA and TGF-β1 levels after CRT are associated with higher risk of distant metastasis and poor overall survival in HNSCC patients.
Author Disclosure: J. Chen: None. Y. Huang: None. S. Kuo: None.